Categories: NewsPharmaceutical

GH Research to Provide Update on Phase 2b Trial with GH001 in TRD

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).

To access the conference call, please register in advance here. A live webcast of the call will be available under “Events & Presentations” in the Investors section of GH Research PLC’s website at ghres.com.

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with treatment-resistant depression (TRD).

About GH001

Our lead product candidate, GH001, is formulated for mebufotenin administration via a proprietary inhalation approach. Based on the observed clinical activity in our completed phase 1/2 GH001-TRD-102 trial, where 87.5% of patients with TRD achieved ultra-rapid remission with our GH001 individualized single-day dosing regimen in the Phase 2 part of the trial, we believe that GH001 has the potential to change the way TRD is treated today.

Investor Relations
Julie Ryan
GH Research PLC
investors@ghres.com

Staff

Recent Posts

BioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH

Investment and Partnership will Allow Manufacturer to Create New Wound Care Products Using Fish Collagen…

5 hours ago

OsteoCentric Technologies Accepts UH Haslam Sports Innovation Center’s First Investment to drive Orthopedic Sports Medicine Innovation

AUSTIN, Texas, March 7, 2025 /PRNewswire/ -- OsteoCentric Technologies, a company dedicated to redefining Orthopedic…

5 hours ago

Waters Corporation to Present at the Leerink Partners Global Healthcare Conference

MILFORD, Mass., March 7, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra…

5 hours ago

IDBS Unveils IDBS Polar Control: Revolutionizing Process Management in BioPharmaceutical Development

WOKING, United Kingdom, March 7, 2025 /PRNewswire/ -- IDBS, a leading global provider of cloud…

11 hours ago

Pharmacy Automation Market worth US$10.00 billion by 2030 with 7.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., March 7, 2025 /PRNewswire/ -- The global Pharmacy Automation Market, valued at…

11 hours ago

Hospital PMI® at 56%; February 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., March 7, 2025 /PRNewswire/ -- Economic activity in the hospital subsector grew in February…

11 hours ago